Рекомендовані дози окремих аміноглікозидів для новонароджених
Interval of Administration | |||||||||
|---|---|---|---|---|---|---|---|---|---|
Aminoglycoside | Route of Administration | Individual Dose | < 30 Week Gestation | 30–34 Week Gestation | ≥ 35 Week Gestation | Comments | |||
Postnatal Age | Postnatal Age | Postnatal Age | |||||||
0–14 days | > 14 days | 0–10 days | > 10 days | 0–7 days | > 7 days | ||||
Amikacin* | IV, IM | 15–17 mg/kg | 15 mg/kg every 48 hours | 15 mg/kg every 24 hours | 15 mg/kg every 24 hours | 15 mg/kg every 24 hours | 15 mg/kg every 24 hours | 17.5 mg/kg every 24 hours | Monitoring of serum drug levels required Peak level target 20–35 mg/L (34.2–59.8 micromol/L) or 10 × MIC; trough < 7 mg/L (12 micromol/L) Dose reduction required for impaired renal function |
Gentamicin*, tobramycin | IV, IM | 4–5 mg/kg | 5 mg/kg every 48 hours | 5 mg/kg every 36 hours | 5 mg/kg every 36 hours | 5 mg/kg every 36 hours | 4 mg/kg every 24 hours | 5 mg/kg every 24 hours | Monitoring of serum drug levels required Peak level target 6–12 mg/L (12.5–25.1 micromol/L) or 10 × MIC; trough < 2 mg/L (4.2 micromol/L) Dose reduction required for impaired renal function |
* Sample should be obtained 30 minutes after a 30-minute IV infusion. | |||||||||
MIC = minimum inhibitory concentration. | |||||||||
Adapted from Bradley JS, Nelson JD: Nelson's Pediatric Antimicrobial Therapy, ed. 24. Itasca, American Academy of Pediatrics, 2018. | |||||||||